{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:51:25Z","timestamp":1780732285700,"version":"3.54.1"},"reference-count":23,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background: Atrial fibrillation (AF) is prevalent in patients undergoing transcatheter aortic valve replacement (TAVR). However, the optimal antithrombotic strategy tailored to individual patient profiles remains unclear. This study aims to evaluate the outcomes of personalized antithrombotic regimens in patients with AF after TAVR. Methods: We enrolled 121 AF patients who underwent TAVR from 2009 to 2023. Patients were grouped into seven groups based on individualized post-procedural antithrombotic regimens. The regimens included the following: single antiplatelet therapy (SAPT) + direct oral anticoagulant (DOAC) (n = 44, 36.3%); DOACs only (n = 25, 20.6%), SAPT + warfarin (n = 17, 14%); dual antiplatelet therapy (DAPT) (n = 13, 10.7%); warfarin only (n = 8, 6.6%); DAPT + warfarin (n = 7, 5.8%); and DAPT + DOACs (n = 7, 5.8%). The study outcomes included incidences of strokes or transient ischemic attacks (TIAs), major bleeding, and survival. Results: The median follow-up was 27 months. The incidence of stroke, TIA, or major bleeding was similar among the seven treatment groups. However, a trend toward a higher rate of stroke was observed in the triple regimen containing warfarin (28.6%); also, the highest rate of major bleeding was observed in the warfarin-only group (25%). Survival for patients discharged and placed under various antithrombotic regimens did not differ significantly despite some numerical variations being present across the groups, with the lowest mortality reported with SAPT + warfarin (7%) and the highest with DAPT + warfarin (57%). Conclusions: This study highlights the outcomes related to stroke, major bleeding, and mortality across personalized antithrombotic regimens in patients with AF after TAVR. While no statistically significant differences were observed, findings emphasize the need for further large-scale studies to define optimal personalized antithrombotic strategies based on individual patient characteristics.<\/jats:p>","DOI":"10.3390\/jpm15040149","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T03:32:53Z","timestamp":1744169573000},"page":"149","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Personalized Antithrombotic Strategies in Patients with Atrial Fibrillation Following Transcatheter Aortic Valve Replacement"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-1642-2149","authenticated-orcid":false,"given":"Razan","family":"Awan","sequence":"first","affiliation":[{"name":"Pharmacy Department, Prince Sultan Cardiac Center, Riyadh 12231, Saudi Arabia"},{"name":"King Fahad Armed Forces Hospital, Jeddah 23311, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5163-5987","authenticated-orcid":false,"given":"Monirah A.","family":"Albabtain","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Prince Sultan Cardiac Center, Riyadh 12231, Saudi Arabia"},{"name":"Research Department, Prince Sultan Cardiac Center, Riyadh 12231, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"AlRasheedi","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Prince Sultan Cardiac Center, Riyadh 12231, Saudi Arabia"},{"name":"Pharmacy Department, King Fahad Specialist Hospital, Buraydah 52366, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7478-2533","authenticated-orcid":false,"given":"Maha","family":"AlHarthi","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Prince Sultan Cardiac Center, Riyadh 12231, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Alanazi","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Prince Sultan Cardiac Center, Riyadh 12231, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0951-7287","authenticated-orcid":false,"given":"Amr A.","family":"Arafat","sequence":"additional","affiliation":[{"name":"Health Research Center, Ministry of Defense Healthcare Services, Riyadh 12485, Saudi Arabia"},{"name":"Adult Cardiac Surgery Department, Prince Sultan Cardiac Center, Riyadh 12231, Saudi Arabia"},{"name":"Cardiothoracic Surgery Department, Tanta University, Tanta 31111, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1126-96","DOI":"10.4244\/EIJ-E-21-00009","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"17","author":"Vahanian","year":"2022","journal-title":"EuroIntervention"},{"key":"ref_2","first-page":"e72","article-title":"2020 ACC\/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1177\/00033197221121012","article-title":"Surgical vs Transcatheter Aortic Valve Replacement in Patients with a Low Ejection Fraction","volume":"74","author":"Arafat","year":"2022","journal-title":"Angiology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43057-022-00094-3","article-title":"Isolated surgical vs. transcatheter aortic valve replacement: A propensity score analysis","volume":"31","author":"Almedimigh","year":"2023","journal-title":"Cardiothorac. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients","volume":"364","author":"Smith","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.jcin.2018.05.042","article-title":"Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement: An Analysis From the STS\/ACC TVT Registry","volume":"11","author":"Vora","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jcin.2016.01.037","article-title":"Prevalence and Impact of Atrial Fibrillation in Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement: An Analysis from the SOURCE XT Prospective Multicenter Registry","volume":"9","author":"Tarantini","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Alghosoon, H., Arafat, A.A., Albabtain, M.A., Alsubaie, F.F., and Alangari, A.S. (2023). Long-Term Effects of Postoperative Atrial Fibrillation following Mitral Valve Surgery. J. Cardiovasc. Dev. Dis., 10.","DOI":"10.3390\/jcdd10070302"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jcin.2019.06.001","article-title":"Antithrombotic Therapy and Cardiovascular Outcomes after Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation","volume":"12","author":"Kosmidou","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.4244\/EIJ-D-15-00259","article-title":"Feasibility and safety of vitamin K antagonist monotherapy in atrial fibrillation patients undergoing transcatheter aortic valve implantation","volume":"12","author":"Geis","year":"2017","journal-title":"EuroIntervention"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/ejcts\/ezs533","article-title":"Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document (VARC-2)","volume":"42","author":"Kappetein","year":"2012","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.jcin.2016.06.025","article-title":"Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement","volume":"9","author":"Durand","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e009963","DOI":"10.1161\/CIRCINTERVENTIONS.120.009963","article-title":"Variation in Antithrombotic Therapy and Clinical Outcomes in Patients with Preexisting Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement","volume":"14","author":"Sherwood","year":"2021","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"74","author":"January","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ejcts\/ezx324","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"52","author":"Falk","year":"2017","journal-title":"Eur. J. Cardio Thorac. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cjca.2019.08.011","article-title":"2019 Canadian Cardiovascular Society Position Statement for Transcatheter Aortic Valve Implantation","volume":"35","author":"Asgar","year":"2019","journal-title":"Can. J. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1161\/CIRCULATIONAHA.114.008643","article-title":"Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation","volume":"129","author":"Steinberg","year":"2014","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0140-6736(17)32165-7","article-title":"A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): An international, cluster-randomised trial","volume":"390","author":"Vinereanu","year":"2017","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ahj.2014.04.007","article-title":"Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3\u20134, 2012","volume":"168","author":"Hess","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR","volume":"385","author":"Unverdorben","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: The ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation","volume":"382","author":"Nijenhuis","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/4\/149\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:13:04Z","timestamp":1760029984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/4\/149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jpm15040149"],"URL":"https:\/\/doi.org\/10.3390\/jpm15040149","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]}}}